BASF's Evonik Math: A Reported 24-Euro Bid, an Unconfirmed Price Tag and a Q3 Date That Matters More

BASF investors woke to a bigger number attached to the Evonik file, but not to a signed deal. Reuters reported that the Ludwigshafen group has lifted its offer for Evonik to 24 euros per share, a figure that would value the specialty chemicals maker at roughly 11.18 billion euros. The agency cited people familiar with the matter, said it could not independently verify the report, and Evonik declined to comment. Handelsblatt and dpa also carried the more-than-11-billion-euro volume. Neither BASF nor Evonik confirmed the figures, and a conclusion remains open.

That distinction — reported price versus agreed purchase price — is the hinge on which the whole story turns. A bid figure describes the possible financial dimension of a transaction. It proves neither a meeting of minds between the two companies nor a completed acquisition. Evonik is reviewing the offer, according to Reuters, and that review is not the same thing as a deal.

What Kamieth Has Actually Promised

One day before the price report surfaced, chief executive Markus Kamieth made the case for a possible takeover in a video message, according to Reuters. He held out job guarantees through 2032, along with the continuation of collective bargaining agreements and social partnership. Those commitments speak to the workforce and to the terms of any combination — a different question from what BASF would pay. And the modality matters: Kamieth held these out as prospects. No completed takeover and no already-implemented employment guarantee can be read into them.

The Capital-Allocation Question Behind the Headline

For anyone holding BASF stock, the sharper issue is not whether a bid lands but whether the company can justify the financial room its strategic agenda demands. A higher offer might smooth the path to agreement; on its own it demonstrates no added value for BASF. That would require the economic case to carry the capital deployed — and the operating business is the yardstick.

Should investors sell immediately? Or is it worth buying BASF?

The stakes are not confined to Evonik. BASF is running several initiatives in parallel. On Tuesday the company signed a memorandum of understanding with Taiwan's economics ministry to expand its Kuanyin site, with additional production capacity for semiconductor materials, an enlarged innovation center and expanded quality analytics. No future earnings contribution can be derived from that yet. On Monday, BASF and Highsun Holding Group agreed non-bindingly to combine their European PA6 activities in a 50-50 joint venture, and the two are also examining the inclusion of worldwide extrusion operations outside North America.

A positive scenario would see these projects cohere into a convincing next step. For that, letters of intent would have to become economically viable agreements. A long list of projects is not a quality seal in itself; execution and earnings prospects are what count.

Buybacks and Bids Are Different Uses of the Same Cash

The share buyback running alongside all this belongs in the same capital-allocation ledger. BASF published an interim notice on Monday about further repurchases. Buybacks and strategic projects are distinct uses of financial means, and what matters for investors is not their mere simultaneity but whether operating performance supports each decision. Weaker results would raise the burden of proof for additional commitments.

The counter-risk runs the other way: a rising financial obligation whose benefit investors have yet to assess. A raised bid would not automatically be good news for BASF. The more demanding the price, the more convincing the economic rationale for a possible takeover would have to be. A valuation that already assumes a successful closing would get ahead of the procedural reality.

October 28 Is the Fixed Anchor

The next confirmed catalyst is the quarterly statement for the third quarter of 2026, announced for October 28, 2026, at 7.00 a.m. CET, with the results call scheduled for 10.30 a.m. CET. That date will serve as the next concrete test of the operating side of the investment case. The figures would not automatically justify a takeover, but they could help establish a more robust baseline for the business.

So long as operating development underpins BASF's strategic room to maneuver, a possible Evonik deal can be read as an additional option — provided its economic benefit stays comprehensible even at a higher price. If that foundation shifts, the emphasis would have to move toward price discipline and the prioritization of individual projects. A confirmed transaction would warrant a fresh assessment of its own. The useful thing about the October date is that it should set the benchmark for the takeover debate, not the other way around: a convincing set of results could support strategic options, but it is no blank check for any purchase price.

Ad

BASF Stock: New Analysis - 23 October

Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BASF analysis...